SynthesisBMC medical ethics2026
Low awareness of medication-related osteonecrosis of the jaw among dentists: a systematic review with a medical and bioethical perspective.
Synthesis in BMC medical ethics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling the landscape of MRONJ awareness (2025): a comprehensive national cross-sectional study of Tunisian dentists' knowledge, attitudes, and practices.BMC oral health · 2026Article
- Bone-modifying therapy in multiple myeloma: a comprehensive review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedication-related osteonecrosis of the Jaw (MRONJ) is a serious adverse drug reaction that can seriously affect the quality of life of patients if not promptly diagnosed and treated. To date, preventive measures have been the most effective strategy for reducing the incidence of MRONJ. The role of dental practitioners in managing patients treated with Bone Modifying Agents (BMAs) varies across countries, with some healthcare systems providing a more structured approach than others. This systematic review aims to investigate the knowledge and awareness of MRONJ among dentists, interpreting the findings from a medical and bioethical perspective. MATERIALS AND
methodsThe protocol for this study was designed following the PRISMA guideline and registered on PROSPERO (CRD420251015032). A systematic review search was conducted in PubMed, Scopus, Web of Science, and Cochrane Database to answer the PICo question: Are dentists well-informed and aware of the risk of MRONJ in patients receiving BMAs? Furthermore, to address potential geographic differences, a country-specific literature review was conducted to compare the level of MRONJ awareness between patients receiving BMAs and dental professionals within the same country. Studies published up to March 2025 were screened.
resultsTwenty-two studies were included in this systematic review. Among the 10,536 dentists involved, 62.8% were well-informed about MRONJ, but only 9.7% were aware of its risk factors. The most common sources of information were university education, followed by scientific journals and specific training courses or conferences. Studies performed in the same countries investigating MRONJ awareness among patients taking BMAs were analyzed. Country-based analysis revealed significant discrepancies between dentists’ (68.5%) and patients’ (19.5%) knowledge and awareness of MRONJ in the USA, Saudi Arabia, Bulgaria, and Brazil. Finally, a bioethical analysis of European legal frameworks on informed consent for pharmacological therapies revealed that adequately informing patients about treatment risks is both an ethical obligation and a legal duty, rooted in constitutional and legislative principles.
conclusionThis systematic review reveals a low level of awareness despite an acceptable level of knowledge among dentists, highlighting an alarming discrepancy. Beyond knowledge of the disease, awareness of its risk factors and preventive strategies is essential for dentists to adopt a personalized and safe workflow for these patient groups. Ensuring personalized therapy requires a structured and collaborative approach based on ethical principles and shared knowledge. Strengthening interprofessional training and teamwork is essential to improving prevention and patient empowerment. PROSPERO REGISTRATION CODE: CRD420251015032.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.